ExoMind™ TMS Frequently Asked Questions
This page is provided for educational purposes, summarizing findings from published research and ongoing clinical studies. It does not constitute medical advice or a guarantee of results. Individual outcomes vary significantly.
Choose a category below to see the questions it covers.
What is the FDA status of ExoMind™ TMS?
The BTL ExoMind™ TMS device is FDA-cleared specifically for the treatment of Major Depressive Disorder (MDD). All other conditions listed below are considered investigational or “off-label” uses of this technology.
What does “off-label” use mean?
“Off-label” refers to the professional use of an FDA-cleared treatment for a condition other than the one for which it was officially cleared. This practice is based on available scientific evidence and clinical judgment. Off-label use involves inherent uncertainties, and benefit is not guaranteed for all patients.
Which conditions are investigational or off-label?
The following uses are investigational; research suggests ExoMind™ may potentially help:
- Sleep, Fatigue & Pain: Insomnia, circadian rhythm disturbance, hypersomnia, chronic fatigue syndrome, fibromyalgia, chronic pain syndromes, tension or migraine headaches, neuropathic pain
- Cognitive & Neurological: Multiple sclerosis, Parkinson’s disease, post-stroke recovery, mild cognitive impairment, early-stage Alzheimer’s, post-COVID “brain fog”, traumatic brain injury, “chemo brain”, age-related cognitive decline
- Addiction & Eating Disorders: Nicotine, alcohol, and drug addiction, smoking cessation, gambling and technology addiction, binge eating and food cravings
- Mood & Trauma: Generalized anxiety disorder, dysthymia, postpartum depression, PMDD, postmenopausal depression, PTSD
- Neurodevelopmental: ADHD, autism spectrum disorder, learning disabilities, Tourette’s
- Other: Obsessive–compulsive disorder